Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.
2.

Integration site selection by retroviral vectors: molecular mechanism and clinical consequences.

Daniel R, Smith JA.

Hum Gene Ther. 2008 Jun;19(6):557-68. doi: 10.1089/hum.2007.148. Review.

3.

Retrovirus-induced oncogenesis and safety of retroviral vectors.

Nair V.

Curr Opin Mol Ther. 2008 Oct;10(5):431-8. Review.

PMID:
18830918
4.

Targeted gene insertion for molecular medicine.

Voigt K, Izsvák Z, Ivics Z.

J Mol Med (Berl). 2008 Nov;86(11):1205-19. doi: 10.1007/s00109-008-0381-8. Epub 2008 Jul 8. Review.

PMID:
18607557
5.

Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors.

Baum C, Kustikova O, Modlich U, Li Z, Fehse B.

Hum Gene Ther. 2006 Mar;17(3):253-63. Review.

PMID:
16544975
6.

[Development and therapeutic application of transposon-based vectors].

Nakanishi H, Higuchi Y, Kawakami S, Yamashita F, Hashida M.

Yakugaku Zasshi. 2009 Dec;129(12):1433-43. Review. Japanese.

7.
8.

Biosafety challenges for use of lentiviral vectors in gene therapy.

Rothe M, Modlich U, Schambach A.

Curr Gene Ther. 2013 Dec;13(6):453-68. Review.

PMID:
24195603
9.

Integration of retroviral vectors.

Gabriel R, Schmidt M, von Kalle C.

Curr Opin Immunol. 2012 Oct;24(5):592-7. doi: 10.1016/j.coi.2012.08.006. Epub 2012 Sep 14. Review.

PMID:
22981243
10.

Mechanisms of retroviral integration and mutagenesis.

Cavazza A, Moiani A, Mavilio F.

Hum Gene Ther. 2013 Feb;24(2):119-31. doi: 10.1089/hum.2012.203. Review.

PMID:
23330935
11.

Biosafety considerations using gamma-retroviral vectors in gene therapy.

Deichmann A, Schmidt M.

Curr Gene Ther. 2013 Dec;13(6):469-77. Review.

PMID:
24195605
12.

Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.

Romano G, Marino IR, Pentimalli F, Adamo V, Giordano A.

Drug News Perspect. 2009 May;22(4):185-96. doi: 10.1358/dnp.2009.22.4.1367704. Review.

PMID:
19536363
13.

Gene therapy in cystic fibrosis.

Flotte TR, Laube BL.

Chest. 2001 Sep;120(3 Suppl):124S-131S. Review.

PMID:
11555567
14.

[Progress in improvement of lentiviral vectors' transcriptional read-through].

He J, Zhang J.

Sheng Wu Gong Cheng Xue Bao. 2011 Nov;27(11):1541-8. Review. Chinese.

PMID:
22393708
15.

Fishing for answers with transposons.

Wadman SA, Clark KJ, Hackett PB.

Mar Biotechnol (NY). 2005 May-Jun;7(3):135-41. Epub 2005 May 5. Review.

PMID:
15864468
16.

[Approaches towards directed DNA integration by the use of retroviral integrases and transposases].

Kniazhanskaia ES, Kondrashina OV, Gottikh MB.

Mol Biol (Mosk). 2011 Nov-Dec;45(6):931-48. Review. Russian.

PMID:
22295563
17.

Current advances in retroviral gene therapy.

Yi Y, Noh MJ, Lee KH.

Curr Gene Ther. 2011 Jun;11(3):218-28. Review.

18.

Understanding lentiviral vector chromatin targeting: working to reduce insertional mutagenic potential for gene therapy.

Papayannakos C, Daniel R.

Gene Ther. 2013 Jun;20(6):581-8. doi: 10.1038/gt.2012.88. Epub 2012 Nov 22. Review.

PMID:
23171920
19.

Sleeping beauty transposon-mediated gene therapy for prolonged expression.

Hackett PB, Ekker SC, Largaespada DA, McIvor RS.

Adv Genet. 2005;54:189-232. Review.

PMID:
16096013
20.

The potential of extrachromosomal replicating vectors for gene therapy.

Calos MP.

Trends Genet. 1996 Nov;12(11):463-6. Review.

PMID:
8973156

Supplemental Content

Support Center